Firmenich

Pura Launches New Allos Scent Collection to Enhance Health and Wellness

Retrieved on: 
Tuesday, March 12, 2024
Online Retail, Retail, Luxury, Other Consumer, Consumer, Home Goods, Specialty, Health, Multimedia, Brain, Collection, Relaxation, Research, Vanilla, Motivation, Emotion, Sleep, Rest, Firmenich, Safety, Perfume

Smart fragrance company Pura is proud to announce the launch of Allos — a collection of four new fragrances specially designed to improve overall health and wellness.

Key Points: 
  • Smart fragrance company Pura is proud to announce the launch of Allos — a collection of four new fragrances specially designed to improve overall health and wellness.
  • View the full release here: https://www.businesswire.com/news/home/20240312024358/en/
    Smart fragrance company Pura is proud to announce the launch of Allos — a collection of four new fragrances specially designed to improve overall health and wellness.
  • Ginger Clementine - Formulated for energy, this scent is made with ingredients that can help increase feelings of energy and excitement.
  • Mint Leaves - Formulated for better focus, this scent is made with ingredients that can help increase feelings of focus and motivation.

dsm-firmenich reports full year 2023 results

Retrieved on: 
Thursday, February 15, 2024
DSM, ANH, Nutrition, Firmenich, Animal nutrition, Vitamin, Culture, Beauty, TTH, Life, Climate change, Element, Acceleration, Science, Annual, HNC, Fine chemical

2 Represents the figures on an IFRS basis, including the Firmenich results as of the merger date May 8, 2023.

Key Points: 
  • 2 Represents the figures on an IFRS basis, including the Firmenich results as of the merger date May 8, 2023.
  • We accelerated our plans for driving through additional self-help measures and advanced the review of all our business segments.
  • In Q4 2023, the program generated an about €10 million savings contribution to Adjusted EBITDA.
  • At the Annual General Meeting on May 7, 2024, dsm-firmenich's Board of Directors will propose a cash dividend of €2.50 per share for the financial year 2023.

Stetson Unveils Legend: The Fragrance for the Next Generation of Stetson Man

Retrieved on: 
Friday, October 13, 2023
Cosmetics, Retail, Online Retail, Specialty, Firmenich, Partnership, Multimedia, Western United States, Music, Legend, Cedrus, Citrus, Paramount, Spice, Hatmaking, Perfume

Scent Beauty, Inc., the industry's leading emerging omnichannel beauty platform, is proud to announce the launch of Stetson Legend, a new luxury fragrance targeting the next generation of Stetson man.

Key Points: 
  • Scent Beauty, Inc., the industry's leading emerging omnichannel beauty platform, is proud to announce the launch of Stetson Legend, a new luxury fragrance targeting the next generation of Stetson man.
  • A modern, elevated expression of the brand’s iconic Western heritage, Stetson Legend embodies the same quality and sophistication that define its iconic hats, boots, apparel and accessories.
  • “Stetson Legend is an exciting and modern scent profile embodying Stetson’s unparalleled heritage, quality and authenticity, and is a significant step forward in updating our fragrance portfolio” says Robert Dundon, CEO of Stetson.
  • This is a scent that’s about wanderlust, being curious, and a life well-lived,” says Ilias Ermenidis, Principal Perfumer at Firmenich and olfactory architect of Stetson Legend.

Trading update and acceleration of strategic actions

Retrieved on: 
Wednesday, June 28, 2023
Acceleration, DSM, Nutrition, Vitamin A, Research, Science, Vitamin, EBITDA, Beauty, ANH, Pinova, Vitamin C, Growth, Adjustment, Perfume, Fine chemical, Dietary supplement, Pharmaceutical industry, Health, Dalry, Firmenich

In addition, it announces the acceleration of initiatives to structurally improve its performance in vitamins.

Key Points: 
  • In addition, it announces the acceleration of initiatives to structurally improve its performance in vitamins.
  • In response, dsm-firmenich has decided to accelerate a series of actions to restructure its vitamin business.
  • Together with the actions announced today, the company remains confident in achieving its mid-term financial targets.
  • These difficult conditions in vitamins are primarily affecting Animal Nutrition & Health, but also, to a lesser extent, Health, Nutrition & Care.

Emmanuel Butstraen appointed as President of Perfumery & Beauty at dsm-firmenich

Retrieved on: 
Monday, May 22, 2023
Integrated Management Concept, University, Integration, MBA, University of Lille, Agricultural engineering, Agricultural productivity, BASF, Firmenich, Perfume, Taste, Management

KAISERAUGST, Switzerland and HEERLEN, Netherlands, May 22, 2023 /PRNewswire/ -- dsm-firmenich is pleased to announce the appointment of Emmanuel Butstraen as the new President of its Perfumery & Beauty business.

Key Points: 
  • KAISERAUGST, Switzerland and HEERLEN, Netherlands, May 22, 2023 /PRNewswire/ -- dsm-firmenich is pleased to announce the appointment of Emmanuel Butstraen as the new President of its Perfumery & Beauty business.
  • Supported by a senior team in the company's Integration Management Office, Emmanuel will continue overseeing the integration while taking on the global leadership role of Perfumery & Beauty.
  • Geraldine Matchett and Dimitri de Vreeze, Co-CEOs of dsm-firmenich, commented: "We are thrilled to announce the appointment of Emmanuel Butstraen as the President of our Perfumery & Beauty business.
  • In his new role as President of Perfumery & Beauty, Emmanuel will report to Co-CEO Dimitri de Vreeze.

COMPLETION OF CONTRIBUTION OF FIRMENICH SHARES TO DSM-FIRMENICH

Retrieved on: 
Tuesday, May 9, 2023
DSM, Exchange, EUR, Offering circular, Firmenich, Exchange offer, Pharmaceutical industry

KAISERAUGST, Switzerland and HEERLEN, Netherlands, May 9, 2023 /PRNewswire/ -- DSM-Firmenich AG (the Company or DSM-Firmenich) announces that the Firmenich Contribution took place yesterday, thereby completing the transactions contemplated by the merger of equals between DSM and Firmenich.

Key Points: 
  • KAISERAUGST, Switzerland and HEERLEN, Netherlands, May 9, 2023 /PRNewswire/ -- DSM-Firmenich AG (the Company or DSM-Firmenich) announces that the Firmenich Contribution took place yesterday, thereby completing the transactions contemplated by the merger of equals between DSM and Firmenich.
  • As a result of the Firmenich Contribution, Firmenich is now a wholly owned subsidiary of DSM-Firmenich.
  • The aggregate consideration received by the Firmenich Shareholders through the Firmenich Contribution is:
    an amount in cash of EUR 3.5 billion; plus
    91,658,354 newly issued DSM-Firmenich Ordinary Shares, representing 34.5% of the Company's total of 265,676,388 aggregate issued DSM-Firmenich Ordinary Shares as of today.
  • Any joint press release issued by the Company, DSM and Firmenich is made available on the website of the Company ( www.dsm-firmenich.com ).

DSM-FIRMENICH ANNOUNCES EVOLUTION OF CEO STRUCTURE PER 1 SEPTEMBER, FOLLOWING COMPLETION OF THE MERGER

Retrieved on: 
Thursday, May 4, 2023
Impax Asset Management Group, DSM, Business, COVID, Treasury, Beauty, Group Control System, PWC, Executive Committee, Pleasure, Control, CFO, Firmenich, Personality, S-1 Executive Committee, Health, Hewlett-Packard, Economics, Management, Fine chemical

The Board of Directors of DSM-Firmenich AG (the Company or DSM-Firmenich) announces an evolution in the company's CEO structure as the company completes its merger of equals with Firmenich International SA on 8 May 2023.

Key Points: 
  • The Board of Directors of DSM-Firmenich AG (the Company or DSM-Firmenich) announces an evolution in the company's CEO structure as the company completes its merger of equals with Firmenich International SA on 8 May 2023.
  • He started his career in PWC followed by Hewlett Packard where he spent seven years in various leadership roles.
  • Ralf will take on the role of CFO and join the Executive Committee of DSM-Firmenich as of 1 September 2023.
  • The DSM and Firmenich merger is extremely exciting, bringing together very complementary cultures and capabilities.

FINAL RESULTS OF THE EXCHANGE OFFER: 96.1% OF DSM ORDINARY SHARES TENDERED

Retrieved on: 
Monday, May 1, 2023
Communication, Enterprise, Failure, Person, SEC Rule 144A, Common stock, ABN, ABN AMRO, Risk, Initial exchange offering, Offering circular, QIB, Acceptance, Letter, Section 4, AMRO Bank, Trustee, Section 16.1 of the Canadian Charter of Rights and Freedoms, Transaction, Naamloze vennootschap, CEST, Section 17 of the Canadian Charter of Rights and Freedoms, Settlement date, Documentation, Euronext Amsterdam, Firmenich, DSM, File, Admitted, Article, Importance, Exchange, Shareholder, EUR, Exchange offer, Security (finance)

KAISERAUGST, Switzerland and HEERLEN, Netherlands and GENEVA, May 1, 2023 /PRNewswire/ -- 

Key Points: 
  • DSM Shareholders who have validly tendered (or defectively tendered, provided that such defect has been waived by the Company) and transferred (geleverd) their DSM Ordinary Shares for acceptance in the Exchange Offer during the Post-Acceptance Period, will receive the Offer Consideration in respect of each tendered DSM Ordinary Share on 3 May 2023 (the Post-Closing Acceptance Settlement Date).
  • The Company accepts all DSM Ordinary Shares that have been validly tendered (or defectively tendered, provided that such defect has been waived by the Company) pursuant to the terms of the Exchange Offer.
  • In addition, DSM will procure the termination of the listing and trading of DSM Ordinary Shares on Euronext Amsterdam as soon as practicable.
  • If a beneficiary to DSM Ordinary Shares located in the United States is unable to make the QIB Confirmations on behalf of itself or the person on whose behalf such DSM Ordinary Shares are held, any DSM-Firmenich Ordinary Shares allotted to such person will instead be transferred to a sales agent, and such DSM-Firmenich Ordinary Shares will be sold on his, her or its behalf with the proceeds being remitted to such person within five days of the Settlement Date, for DSM-Firmenich Ordinary Shares allotted in exchange for DSM Ordinary Shares tendered during the Acceptance Period, or within five days of the Post-Closing Acceptance Settlement Date, for DSM-Firmenich Ordinary Shares allotted in exchange for DSM Ordinary Shares tendered during any Post-Closing Acceptance Period.

FINAL RESULTS OF THE EXCHANGE OFFER: 96.1% OF DSM ORDINARY SHARES TENDERED

Retrieved on: 
Monday, May 1, 2023
Communication, Enterprise, Failure, Person, SEC Rule 144A, Common stock, ABN, ABN AMRO, Risk, Initial exchange offering, Offering circular, QIB, Acceptance, Letter, Section 4, AMRO Bank, Trustee, Section 16.1 of the Canadian Charter of Rights and Freedoms, Transaction, Naamloze vennootschap, CEST, Section 17 of the Canadian Charter of Rights and Freedoms, Settlement date, Documentation, Euronext Amsterdam, Firmenich, DSM, File, Admitted, Article, Importance, Exchange, Shareholder, EUR, Exchange offer, Fine chemical, Security (finance)

KAISERAUGST, Switzerland, HEERLEN, the Netherlands and GENEVA, May 1, 2023 /PRNewswire/ -- DSM-Firmenich AG (the Company or DSM-Firmenich), DSM, and Firmenich are pleased to announce that during the Post-Closing Acceptance Period, which expired on 28 April 2023 at 17:40 CEST, 16,578,846 DSM Ordinary Shares have been tendered for acceptance in the Exchange Offer, representing approximately 9.6% of DSM's aggregate issued and outstanding ordinary share capital and an aggregate value of approximately EUR 1.97 billion.1 Together with the DSM Ordinary Shares already held by the Company on the date hereof, the Company will hold a total of 167,321,557 DSM Ordinary Shares, representing approximately 96.1% of DSM's aggregate issued and outstanding ordinary share capital.

Key Points: 
  • DSM Shareholders who have validly tendered (or defectively tendered, provided that such defect has been waived by the Company) and transferred (geleverd) their DSM Ordinary Shares for acceptance in the Exchange Offer during the Post-Acceptance Period, will receive the Offer Consideration in respect of each tendered DSM Ordinary Share on 3 May 2023 (the Post-Closing Acceptance Settlement Date).
  • The Company accepts all DSM Ordinary Shares that have been validly tendered (or defectively tendered, provided that such defect has been waived by the Company) pursuant to the terms of the Exchange Offer.
  • In addition, DSM will procure the termination of the listing and trading of DSM Ordinary Shares on Euronext Amsterdam as soon as practicable.
  • If a beneficiary to DSM Ordinary Shares located in the United States is unable to make the QIB Confirmations on behalf of itself or the person on whose behalf such DSM Ordinary Shares are held, any DSM-Firmenich Ordinary Shares allotted to such person will instead be transferred to a sales agent, and such DSM-Firmenich Ordinary Shares will be sold on his, her or its behalf with the proceeds being remitted to such person within five days of the Settlement Date, for DSM-Firmenich Ordinary Shares allotted in exchange for DSM Ordinary Shares tendered during the Acceptance Period, or within five days of the Post-Closing Acceptance Settlement Date, for DSM-Firmenich Ordinary Shares allotted in exchange for DSM Ordinary Shares tendered during any Post-Closing Acceptance Period.

EXCHANGE OFFER DECLARED UNCONDITIONAL

Retrieved on: 
Monday, April 17, 2023
Communication, Failure, European, Person, SEC Rule 144A, Common stock, Sub, ABN, ABN AMRO, Article, Risk, Initial exchange offering, Offering circular, QIB, Acceptance, Letter, AMRO Bank, Trustee, Section 16.1 of the Canadian Charter of Rights and Freedoms, Transaction, Naamloze vennootschap, CEST, Council, Admission, Section 17 of the Constitution Act, 1867, Triangle, Settlement date, Disclosure, EGM, Section 16 of the Canadian Charter of Rights and Freedoms, Documentation, Euronext Amsterdam, Firmenich, Withdrawal, DCC, DSM, European Parliament, File, Admitted, Importance, Exchange, Shareholder, Settlement, ISIN, Exchange offer, EC, Security (finance), Cryptocurrency, Bank, Liquidation

KAISERAUGST, Switzerland and HEERLEN, Netherlands and GENEVA, April 17, 2023 /PRNewswire/ --

Key Points: 
  • After settlement of the Post-Closing Acceptance Period, the Company intends to implement either the Buy-Out or the Post-Offer Merger and Liquidation
    DSM and Firmenich boards are very pleased to announce that the Company hereby declares the Exchange Offer unconditional.
  • As a result, the Exchange Offer will be settled on 20 April 2023 and the Firmenich Contribution will occur on 8 May 2023.
  • This announcement contains selected, condensed information regarding the Exchange Offer and does not replace the Offering Circular.
  • Accordingly, to be eligible to receive DSM-Firmenich Ordinary Shares under the Exchange Offer, each DSM Shareholder that is a U.S.